Business Context and Reporting Period
This Form 8-K filing by Minerva Neurosciences, Inc. (NERV) covers the period ending September 8, 2022. The report details a corporate action regarding the listing status of the company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing transfer event and does not contain financial statement data.
Material Changes
- Listing Transfer: The Company's common stock listing was transferred from The Nasdaq Global Market to The Nasdaq Capital Market.
- Approval Date: Nasdaq approved the transfer application on September 8, 2022.
- Effective Date: The transfer became effective at the opening of business on September 12, 2022.
- Trading Symbol: The stock continues to trade under the symbol "NERV."
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the listing transfer. The filing does not provide forward-looking guidance, discuss specific risks, or detail contingencies beyond the administrative change in listing venue. A press release dated September 9, 2022, regarding this transfer is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the effective date of the listing transfer (September 12, 2022) to confirm trading venue changes.
- Confirm that the trading symbol remains "NERV" post-transfer.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the reasons for the transfer.
- Check subsequent filings for financial data, as this 8-K does not contain performance metrics.